Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Iscover er større end risiciene ved behandling af aterotrombotiske hændelser.
The Committee for Medicinal products for Human Use (CHMP) decided that Iscover’ s benefits are greater than its risks for patients at risk of atherothrombotic events.